Nhanganyaya kuSomaglutide
Somaglutide chizvarwa chitsva cheGLP-1 (glucagon se peptide-1) analog yakagadzirwa naDaminol uye NovoNordisk.Somaglutide ndeyekureba-kuita dosage fomu yakagadziridzwa yakavakirwa pane yekutanga dhizaini yeLilalutide, ine mhedzisiro iri nani pakurapa kwerudzi rwechipiri chirwere cheshuga.Novo Nordisk akapedza 6 PChemicalbookbaseIIIa zvidzidzo paSomaglutide jekiseni, uye akatumira mutsva wekunyoresa zvinodhaka chikumbiro chevhiki nevhiki jekiseni reSomaglutide kuUS Food and Drug Administration (FDA) muna Zvita 5, 2016, pamwe nemvumo yekushambadzira (MAA) Mushonga weEurope Autongi (EMA).Kune rumwe rutivi, kamwe chete zuva nezuva kugadzirirwa kwemuromo kweSomaglutide ikozvino muchipatara chikamu III.
Usage
Somaglutide ndeyekureba-inoita dosage fomu yakagadziridzwa yakavakirwa pane yekutanga chimiro che liraglutide, ine mhedzisiro irinani mukurapa kwerudzi rwechipiri chirwere cheshuga.
Tsvakurudzo
Semeglutide inyowani GLP-1 analog iyo inobaiwa pasi pecutaneously kamwe pasvondo.Somaglutide inogara kwenguva refu GLP-1 analog yakagadzirwa naNovo Nordisk kweimwe nguva / w subcutaneous jekiseni.Kuenzaniswa ne liraglutide, Somaglutide ine cheni refu yemafuta uye yakawedzera hydrophobicity.Zvisinei, Somaglutide inoshandurwa neketani pfupi PEG, uye hydrophilicity yayo inowedzerwa zvikuru.Mushure mekugadzirisa PEG, haigoni kungobatana chete ne albumin, kuvhara nzvimbo ye hydrolysis yeDPP-4 enzyme, asi zvakare kuderedza kubuda kwetsvo, kurebesa hafu yehupenyu hwehupenyu uye kuwana mhedzisiro yenguva refu.Novo Nordisk's Somaglutide yakaturika DPP-4's Sigliptin, uye GLP-1's muvambi, yakareba-acting exenatide (inofanira kugadzirirwa kukwikwidzana musoro nemusoro neLily's trucity. Kudheerera kwave kuri pamusika kwenguva yakareba).Mukuedza, chiyero chepamusoro cheSomicalbook chakadzikira A1C1.6%, uye iyo yakanyanya kurasikirwa uremu yaive 6 kg.Somaglutide yakashandiswa kuongorora kushanda uye kuchengeteka kwe1.0mg Somaglutide kana ichienzaniswa ne2.0mg Exenatide kamwe chete pavhiki muvarwere ve813 vane chirwere cheshuga 2.Nguva yekuedzwa yaive mavhiki e56, uye varwere vakatora 1-2 anti-diabetes zvinodhaka nemuromo panguva imwe chete.Muna Zvita 2017, FDA yakabvumidza zviri pamutemo vhiki nevhiki GLP-1 hypoglycemic drug Somaglutide yakagadzirwa neNovoNordisk kuti itengeswe pasi pezita rekutengesa reOzempic.Zvinoenderana nemakiriniki ekuedzwa data, Ozempic inogona kuderedza HbA1c nhanho kana ichienzaniswa ne placebo, Januvia yeMerck, Bydureon yeAstraZeneca uye Lantus yeSanofi.Mushonga wacho wakaratidzawo kukwanisa kubatsira varwere kuderedza uremu.
Nguva yekutumira: Zvita-25-2022